Search results
KEEP & PANTHERx Rare Forge Innovative Partnership to Advance the Specialty Therapy Experience in the...
FOX 4 Kansas City· 2 days agoAn exciting advancement for the specialty pharmacy industry, KEEP announced a strategic partnership...
KEEP & PANTHERx Rare Forge Innovative Partnership to Advance the Specialty Therapy Experience in the...
FOX 59 Indianapolis· 2 days agoAn exciting advancement for the specialty pharmacy industry, KEEP announced a strategic partnership...
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Morningstar· 6 days agoBy Ben Glickman Kura Oncology said Monday it received a breakthrough therapy designation from regulators for ziftomenib, its potential treatment for a form of leukemia. The San Diego-based biopharmaceutical company said the U.S. Food and
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 3 days agoShanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society...
Morningstar· 4 days ago– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO – STAMFORD
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
WTNH-TV New Haven· 4 days agoSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical...
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest...
Morningstar· 3 days agoSUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis ...
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
Proactive Investors· 5 days agoLisata Therapeutics Inc (NASDAQ:LSTA) CEO David J. Mazzo discusses the oncology company's focus and...
Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug
Medscape· 5 days agoThe factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal...
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 6 days agoKura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company, has announced that...